Navigation Links
Egenix, Inc. Announces New Director
Date:11/5/2012

MILLBROOK, N.Y., Nov. 5, 2012 /PRNewswire/ -- Donald Fresne, President and CEO of Egenix, Inc., is pleased to announce the appointment of Rainer Fuchs, Ph.D. to its Board of Directors. Dr. Fuchs is a former V.P. of Biogen Idec and currently Chief Information Officer at Harvard Medical School in Cambridge, Massachusetts. Dr. Fuchs will be a substantial asset to the company.  Additionally, the Company has added the following scientist to complete its Drug Development Team: Bob Bishop, Ph.D., Jerry Shipps, Ph.D., Alan Cooper, Ph.D., and Arshad Siddiqui, Ph.D.

Egenix is a privately held, New York-based biotechnology company focused on the development of innovative cancer therapeutics. The company's therapeutic platform technology consists of small molecule drugs applicable for the treatment and prevention of a broad spectrum of cancers. Our lead drug candidates inhibit the "translation initiation factor" eIF4E, specifically blocking production of multiple cancer promoting proteins and promoting apoptosis (programmed cell death) and upregulation of tumor suppressor genes. The company licensed this technology from Harvard Medical School in 2007. eIF4E is an important cancer therapeutic target because every function necessary for cancer growth and metastasis is influenced or mediated by a gene product that is regulated by this translation initiation factor. Data from human cancer xenograft studies using two of our lead compounds tested against breast cancer and melanoma demonstrated 100% tumor inhibition and 20% to 30% tumor reduction. For more information visit www.egenixinc.com.


'/>"/>
SOURCE Egenix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. BioRestorative Therapies Announces Stock Trading On OTC Bulletin Board
2. WebMD Announces Third Quarter Financial Results
3. Life Technologies Announces Third Quarter 2012 Results
4. HealthTech Capital Announces Awards for the HealthTech Conference 2012 - Building a Business in the New HealthTech Ecosystem
5. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
6. MiMedx Group Announces Record Third Quarter Results And Raises Revenue Estimates For The Year
7. IntelliCell BioSciences Announces Myron Z. Holubiak Joins the IntelliCell BioSciences Board of Directors
8. Synthetic Biologics Announces $10.8 Million Financing
9. Haemonetics Reports Second Quarter Fiscal 2013 Revenue Up 22%, Organic Revenue Up 6% and Adjusted EPS of $0.90, Reaffirms Fiscal 2013 Guidance and Announces Two-For-One Stock Split
10. Altogen Labs Announces Patent Filing for Bioremediation Process and Oil Spill Cleanup Products
11. Techne Corporation Declares Dividend And Announces An Increase In Its Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... NC (PRWEB) , ... January 16, 2017 , ... ... company, received the prestigious Tibbetts Award from the U.S. Small Business Administration. ... “that have created a significant economic or social impact […] and are considered the ...
(Date:1/13/2017)... Research and Markets has announced the addition of the "Global ... ... CAGR of 16.83% during the period 2017-2021. The report ... market for 2017-2021. To calculate the market size, the report considers the ... also includes a a discussion of the key vendors operating in this ...
(Date:1/12/2017)... ... January 12, 2017 , ... Each year, Crain’s Detroit Business News ranks the ... evaluates the patent estate of a company, its impact and significance, and the likelihood ... the way in technologies that transform energy sources such as low dose X-ray and ...
(Date:1/12/2017)... 12, 2017   Protein Sciences Corporation , ... Flublok Influenza Vaccine ®, announced today that ... good safety results and induced strong neutralizing antibodies ... product is expected to advance into human clinical ... the Institute of Technology in Immunobiologicals of the ...
Breaking Biology Technology:
(Date:1/6/2017)... LA JOLLA, Calif. , Jan. 6, 2017 ... Phase 1 safety studies in healthy volunteers of ... CM4620, intended to treat acute pancreatitis. ... pancreas, is typically a mild disorder, but can ... to organ failure and sepsis, where extended hospital ...
(Date:1/3/2017)... , Jan. 3, 2017 Onitor, provider of ... of Onitor Track, an innovative biometric data-driven program designed ... this month at the 2017 Consumer Electronics Show (CES) ... In the U.S., the World Health Organization (WHO), ... two-thirds of adults who are overweight or obese. WHO ...
(Date:12/19/2016)... España y TORONTO , 19 de diciembre de ... Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, un anticuerpo ... varios tipos de tumor en 2017, con múltiples sitios previstos a ... ... con objetivo en el factor inhibidor de leucemia (LIF), una citoquina ...
Breaking Biology News(10 mins):